Nobazit, capsules 250 mg 20 pcs

Pharmacotherapeutic group: Antiviral drug.

ATC code: J05 AH

Pharmacological properties

Pharmacodynamics

Nobazit® is an antiviral agent, a derivative of isonicotinic acid. It effectively suppresses influenza viruses and other agents of acute respiratory viral infections due to the direct (inhibitory) influence on the process of virus penetration through the cell membrane.
It possesses interferonogenic properties, increases the concentration of endogenous interferon (interferon alpha and interferon gamma) in blood plasma by 3-4 times. Increases body resistance to viral infections.
Reduces acute clinical manifestations of viral intoxication, helps to reduce the duration of the disease.

Pharmacokinetics

After oral administration enisamide iodide quickly enters the blood, its maximum concentration in the blood is observed 2-2.5 hours after consumption. Enisamy iodide and its metabolites circulate in the bloodstream for a long time (half-life is 13.5-14 hours), are metabolized in the liver and are quickly eliminated from the tissues (half-life is 2-3 hours). It is 90-95% excreted in the urine as metabolites.

Indications

Treatment of influenza and other acute respiratory viral infections, including as part of complex therapy.

Pharmacological effect

Pharmacotherapeutic group: Antiviral agent.

ATX code: J05 AX

Pharmacological properties

Pharmacodynamics

Nobasit® is an antiviral agent derived from isonicotinic acid. Effectively suppresses the effect of influenza viruses and other pathogens of acute respiratory viral infections (ARVI) due to the direct (inhibitory) effect on the process of penetration of viruses through the cell membrane.
It has interferonogenic properties, helps increase the concentration of endogenous interferon (interferon alpha and interferon gamma) in the blood plasma by 3-4 times. Increases the body’s resistance to viral infections.
Reduces acute clinical manifestations of viral intoxication and helps reduce the duration of the disease.

Pharmacokinetics

After oral administration, enisamium iodide quickly enters the blood; its maximum concentration in the blood is observed 2-2.5 hours after consumption. Enisamium iodide and its metabolites circulate in the bloodstream for a long time (half-life is 13.5-14 hours), metabolized in the liver and quickly eliminated from tissues (half-life is 2-3 hours). 90-95% is excreted in the urine in the form of metabolites.

Special instructions

The drug should be prescribed with caution to patients with thyroid diseases, especially hyperthyroidism.

Impact on the ability to drive vehicles and machinery

Taking Nobasit® does not affect the ability to drive vehicles and operate various mechanical equipment.

Active ingredient

Enisamia iodide

Composition

One tablet contains:

active substance:

N-methyl-4-benzylcarbamidopyridinium iodide (enisamium iodide) (based on 100% anhydrous substance) – 250 mg.

excipients (core):

lactose monohydrate (milk sugar) – 66.8 mg,

microcrystalline cellulose (vivapur 101) – 20.0 mg,

sucrose (refined sugar) – 18.0 mg,

povidone (low molecular weight medical polyvinylpyrrolidone or plasdon K-17) – 7.2 mg,

copovidone (plasdon S-630) – 2.8 mg,

crospovidone (polyplasdone XL-10) – 7.6 mg,

talc – 3.8 mg,

calcium stearate – 3.8 mg.

excipients (shell): Aquarius Prime BAN314047 Yellow – 12 mg (hypromellose – 7.92 mg, titanium dioxide – 2.6874 mg, caprylic/caprylate (caprylic/capric triglyceride) – 1.08 mg, iron dye yellow oxide – 0.084 mg, iron dye red oxide – 0.0006 mg, quinoline yellow dye – 0.228 mg).

Pregnancy

Use during pregnancy and breastfeeding is contraindicated.

Contraindications

Hypersensitivity to any of the components of the drug.

Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Sucrase/isomaltase deficiency, fructose intolerance.

Children under 18 years of age, pregnancy, lactation period.

The presence of allergic reactions, regardless of the nature of the allergen in the anamnesis.

Severe organic damage to the liver and kidneys.

Side Effects

Allergic reactions: hypersensitivity reactions, including skin rashes, urticaria, angioedema, itching.

From the digestive system: dryness and bitter taste in the mouth, swelling of the oral mucosa, hypersalivation, yellow tongue, nausea, vomiting, heartburn, abdominal pain, heaviness in the right hypochondrium, diarrhea, bloating.

From the respiratory system: shortness of breath, throat irritation.

In the post-registration period, the following adverse reactions were observed in isolated cases: headache, dizziness, weakness, fluctuations in blood pressure.

If you experience side effects indicated in the instructions or they get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Interactions with other drugs have not been sufficiently studied.

Nobasit® enhances the effect of antibacterial and immunomodulatory agents.

It is advisable to combine this drug with ascorbic acid and other vitamins. Nobasit® can also be prescribed simultaneously with the use of recombinant interferon.

If you are using the above or other medications (including over-the-counter medications), consult your doctor before using Nobasit®.

Overdose

In case of an overdose of the drug, the side effects described in the corresponding section may increase. When they appear, gastric lavage and symptomatic treatment are performed.

Storage conditions

In a dry place, protected from light, at a temperature of 2 to 25°C.

Keep out of the reach of children.

Shelf life

3 years. Do not use after the expiration date stated on the package.

Manufacturer

Irbitsky Chemical Plant, Russia